<DOC>
	<DOCNO>NCT02016105</DOCNO>
	<brief_summary>The aim study demonstrate equivalent efficacy similarity safety profile GP2017 Humira® patient moderate severe chronic plaque-type psoriasis .</brief_summary>
	<brief_title>Study Demonstrate Equivalent Efficacy Compare Safety Biosimilar Adalimumab ( GP2017 ) Humira</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Men woman least 18 year age time screen Chronic plaquetype psoriasis diagnose least 6 month randomization Moderate severe psoriasis define baseline : PASI score 12 great Investigator´s Global Assessment score 3 great ( base scale 0 4 ) , Body Surface Area affect plaquetype psoriasis 10 % great Chronic plaquetype psoriasis patient previously receive phototherapy systemic psoriasis therapy least candidate therapy opinion investigator . Forms psoriasis chronic plaquetype Druginduced psoriasis Ongoing use prohibit psoriasis treatment Previous exposure adalimumab Active ongoing inflammatory disease psoriasis might confound evaluation benefit treatment adalimumab Other In/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>plaque type psoriasis</keyword>
	<keyword>equivalent efficacy</keyword>
	<keyword>safety immunogenicity</keyword>
	<keyword>GP2017</keyword>
	<keyword>Humira®</keyword>
</DOC>